Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea

Endocrine therapy is the mainstay treatment for hormone receptor-positive ductal carcinoma in situ. The aim of this study was to examine the long-term secondary malignancy risk of tamoxifen therapy. The data of patients diagnosed with breast cancer between January 2007 and December 2015 were retriev...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dooreh, Oh, Jooyoung, Seok, Jeong-Ho, Lee, Hye Sun, Jeon, Soyoung, Yoon, Chang Ik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954831/
https://www.ncbi.nlm.nih.gov/pubmed/36832280
http://dx.doi.org/10.3390/diagnostics13040792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954831/
https://www.ncbi.nlm.nih.gov/pubmed/36832280
http://dx.doi.org/10.3390/diagnostics13040792

Ejemplares similares